Press Releases Simcere Pharmaceutical Group Limited

Equities

2096

HK0000658531

Pharmaceuticals

Market Closed - Hong Kong S.E. Other stock markets 04:08:49 2026-03-10 am EDT			5-day change	1st Jan Change
11.97 ^HKD	+2.75%		+3.55%	-

Feb. 25	Simcere Pharmaceutical Group Limited acquired Xianwei Biotechnology Co., Ltd.	CI
Feb. 25	Simcere Pharmaceutical Forecasts Up to 94% Boost in 2025 Profit	MT

Press Releases

Dec. 23	Ipsen expands early development pipeline with Simcere Zaiming's innovative antibody drug conjugate	AQ
25-10-16	NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States	AQ
25-06-18	Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma	PR
25-01-13	Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma	PR
25-01-13	AbbVie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma	PR
24-09-03	Simcere Zaiming collaborates with TargetRx to introduce a third-generation ALK inhibitor	AQ
24-09-03	TargetRx Signs Collaboration Agreement with Simcere Zaiming	AQ
24-06-26	Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA	PR
23-11-21	Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China	AQ
22-12-20	PHASE II/III CLINICAL TRIAL OF SIMCERE'S 3CL-TARGETING ANTI-SARS-COV-2 DRUG CANDIDATE COMPLETE ALL PATIENTS ENROLLMENT	PR
22-09-28	Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc	PR
22-09-05	Simcere Pharmaceutical Announces Financial Results for 2022 H1: 27% Year-Over-Year Revenue Growth, with Innovative Drugs Accounting for 65.4% of Total Revenue	PR
22-04-18	Proprietary SARS-CoV-2 3CL Inhibitor Rapidly Progressing in Clinical Trials, Market Approval of Trilaciclib Expected in China, Simcere Reveals Global Innovation Ambition on R&D Day	PR
22-04-06	SIMCERE PHARMA (HK.2096) to host 2022 R&D Day	PR
22-02-23	Simcere Pharma (2096.HK) Announces a Positive Profit Alert	PR
21-09-20	PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2021 Financial Results and Operational Progress	DJ
21-06-28	PRESS RELEASE : Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Financial Guidance	DJ
21-06-28	PRESS RELEASE : Vivoryon Therapeutics and Simcere Announce Strategic Regional Licensing Partnership to Develop and Commercialize N3pE Amyloid-targeting Medicines to Treat Alzheimer's Disease in Greater China	DJ
21-04-28	Simcere Pharmaceutical : FURTHER ANNOUNCEMENT PROFIT FORECAST IN RELATION TO DISPOSAL OF SUBSIDIARIES	PU
21-04-19	PRESS RELEASE : Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801	DJ
21-04-16	Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE APPROVAL ON CLINICAL TRIAL APPLICATION FOR THE ADDITION OF NEW INDICATIONS OF TRILACICLIB FOR INJECTION	PU
21-04-15	Simcere Pharmaceutical : CHANGE IN USE OF PROCEEDS	PU
21-04-13	Simcere Pharmaceutical : VOLUNTARY ANNOUNCEMENT IN RELATION TO THE CLINICAL TRIAL APPROVAL FOR SIM-307 ISSUED BY THE CENTER FOR DRUG EVALUATION OF NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF PRC	PU
21-03-31	Simcere Pharmaceutical : RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF OPERATING OFFICER	PU
21-03-25	Simcere Pharmaceutical : Revised Terms of Reference of the Strategy Committee	PU